- Home
- DEA vs SVRA Comparison
DEA vs SVRA Comparison
Compare DEA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEA | SVRA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | DEA | SVRA |
|---|---|---|
| Price | $24.18 | $5.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $24.99 | $7.33 |
| AVG Volume (30 Days) | 421.7K | ★ 1.3M |
| Earning Date | 02-23-2026 | 03-26-2026 |
| Dividend Yield | ★ 7.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $334,212,000.00 | N/A |
| Revenue This Year | $9.60 | N/A |
| Revenue Next Year | $8.24 | N/A |
| P/E Ratio | $81.20 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $19.33 | $1.89 |
| 52 Week High | $29.49 | $7.01 |
Technical Indicators
Market Signals| Indicator | DEA | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.44 | 42.02 |
| Support Level | $23.00 | $5.10 |
| Resistance Level | $23.44 | $5.71 |
| Average True Range (ATR) | 0.52 | 0.32 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 100.00 | 17.99 |
Price Performance
Historical ComparisonAbout DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.